The phenotypical features and risk factors for progression of endometrial stromal tumors


Endometial stromal Sarcoma
Fenotypic features
Stromal Endometriosis

How to Cite

Barbakadze , L. ., Nikoloz Kintraia, Jikurashvili, M., & George Burkadze. (2022). The phenotypical features and risk factors for progression of endometrial stromal tumors. GEORGIAN SCIENTISTS, 4(2), 165–175.


Endometrial stromal sarcomas are mesenchymal tumors and constitute 0,2-1% of all the malignant uterine pathologies and 6-20% of uterine sarcomas. Commonly they arise in 42-53 year old women. Unlike epithelial tumors, that are having better prognosis, uterine sarcomas are known to have bad prognosis. The recurrence rate and the risk of distant metastasis is high. Local recurrence can be even seen 20-30 years after primary diagnosis and therapy. Radical surgery stands as the primary therapeutic method, often with adjuvant radio- and chemotherapy. Due to the low incidence of endometrial stromal sarcomas, only few things are known about the risk factors of bad outcome and its optimal management.


Subbaraya, S., Murthy, S. S., & Devi G, S. (2020). Immunohistochemical and

Molecular Characterization of endometrial stromal sarcomas. Clinical Pathology, 13

Hrzenjak A. JAZF1/SUZ12 gene fusion in endometrial stromal sarcomas. Orphanet J Rare Dis. 2016;11:15

Lan, C. , Huang, X. , Lin, S. , Cai, M. , Liu, J. Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review. Gynecol Obstet Invest. 2012; 74(4): 288–297

Stemme S, Ghaderi M, Carlson JW. Diagnosis of endometrial stromal tumors. Am J Clin Pathol. 2013;141:133-139

Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynecol Obs. 2018;143:51-58

Stemme S, Ghaderi M, Carlson JW. Diagnosis of endometrial stromal tumors: a clinicopathologic study of 25 biopsy specimens with identification of problematic areas. Am J Clin Pathol 2014;141:133–139

Nucci MR. Practical issues related to uterine pathology: endometrial stromal tumors. Mod Pathol. 2016;29 Suppl 1:S92-S103

Albores-Saavedra J, Dorantes-Heredia R, Chable-Montero F et al. Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity. Am J Clin Pathol 2014;141:850–855

Sciallis AP, Bedroske PP, Schoolmeester JK et al. Highgrade endometrial stromal sarcomas: a clinicopathologic study of a group of tumors with heterogenous morphologic and genetic features. Am J Surg Pathol 2014;38:1161–1172

Lee CH, Hoang LN, Yip S et al. Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Mod Pathol 2014;27:751–757

Shah VI, McCluggage WG. Cyclin D1 does not distinguish YWHAE-NUTM2 high-grade endometrial stromal sarcoma from undifferentiated endometrial carcinoma. Am J Surg Pathol 2015;39:722–724

Gremel G, Liew M, Hamzei F et al. A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer 2015;136:1608–1618

Perri F, Pisconti S, Della Vittoria Scarpati G. P53 mutations and cancer: a tight linkage. Ann Transl Med. 2016;4(24):522. doi:10.21037/atm.2016.12.40

Roy M, Kumar S, Bhatla N, et al. Androgen Receptor Expression in Endometrial Stromal Sarcoma: Correlation With Clinicopathologic Features. Int J Gynecol Pathol. 2017;36(5):420-427

Przybyl J, Kowalewska M, Quattrone A, et al. Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. JCI Insight. 2017;2(11):e94033

Yoon JY, de Kock L, Stewart CJR, et al. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. Cancer Treat Res Commun. 2021;27:100363

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.


Download data is not yet available.


Metrics Loading ...